Efficacy and safety of switching to pasireotide LAR monotherapy or in combination with pegvisomant in acromegaly patients controlled with combination therapy of first-generation somatostatin analogues and pegvisomant (PAPE Study): A prospective, open-label 48-week study

Authors
Category Primary study
JournalEndocrine Reviews
Year 2018
This article has no abstract
Epistemonikos ID: 10226bbd2edb6f06dfa8a6775fa4196317a1c556
First added on: Jul 02, 2024